- In January 2025, CSL Behring, announced the launch of its Antithrombin (AT) concentrate, which is used for managing hereditary antithrombin deficiency, a condition that increases the risk of blood clots. The new product is designed for intravenous administration and aims to provide enhanced thrombotic risk management for patients undergoing surgery or those with acute thrombotic episodes. The launch follows extensive clinical trials that demonstrated the product’s efficacy and safety in managing thrombotic risk
- In December 2024, Grifols, expanded its antithrombin concentrate product line by introducing a new formulation that offers improved stability at room temperature. The new formulation provides healthcare providers with a more convenient and cost-effective option for managing antithrombin deficiency in both hospital and outpatient settings. Grifols emphasized the ease of administration and its potential to improve patient outcomes by reducing the frequency of hospital visits for intravenous infusions
- In November 2024, Octapharma AG announced new findings at the International Society on Thrombosis and Haemostasis (ISTH) 2024 Congress, revealing the effectiveness of its Octaplex antithrombin concentrate for patients with hereditary antithrombin deficiency who are undergoing major surgeries. The data showed a significant reduction in the incidence of venous thromboembolism (VTE) following administration, reinforcing the importance of early intervention in surgery to reduce thrombotic risks
- In October 2024, LFB USA introduced a new antithrombin concentrate in the U.S. market, offering a higher purity level and faster infusion rate for patients requiring urgent thromboprophylaxis. This new product has been designed to address the unmet need for quicker and more effective treatment options for patients at risk of clotting disorders, particularly in critical care units
